Heart Diseases  >>  Tekturna (aliskiren)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

7 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tekturna (aliskiren) / PDL
ALOFT, NCT00219011 / 2004-004014-16: " - Aliskiren Observation of Heart Failure Treatment": Efficacy and Safety of Aliskiren Added on Top of Standard Therapy in Adults (≥ 18 Years) With Stable Heart Failure

Completed
3
280
US, Europe
aliskiren
Novartis
Heart Failure
02/07
02/07
ALLAY, NCT00219141 / 2005-000856-34: Aliskiren in Combination With Losartan Compared to Losartan on the Regression of Left Ventricular Hypertrophy in Overweight Patients With Essential Hypertension

Completed
3
460
US, Europe, RoW
Aliskiren 150/300 mg, Losartan 50/100 mg, Aliskiren placebo, Losartan 50/100 mg placebo
Novartis Pharmaceuticals
Hypertension, Left Ventricular Hypertrophy, Overweight
11/07
11/07
NCT00414609 / 2006-001704-37: Safety and Efficacy of Aliskiren in Post Myocardial Infarction Patients (ASPIRE)

Completed
3
820
US, Canada, Europe, RoW
Aliskiren, Tekturna®, placebo
Novartis
Myocardial Infarction
09/09
07/11
ASTRONAUT, NCT00894387 / 2009-010236-18: Six Months Efficacy and Safety of Aliskiren Therapy on Top of Standard Therapy, on Morbidity and Mortality in Patients With Acute Decompensated Heart Failure

Completed
3
1639
Europe, Canada, US, RoW
Aliskiren, Aliskiren®,, Tekturna®,, Rasilez®,, SPP100, Placebo
Novartis Pharmaceuticals
Acute Decompensated Heart Failure, Congestive Heart Failure
08/12
08/12
AQUARiUS, NCT00853827 / 2008-006447-40: Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients

Completed
3
613
US, Canada, Europe, RoW
Placebo, Aliskiren
Novartis Pharmaceuticals, The Cleveland Clinic
Coronary Artery Disease (CAD), Coronary Atherosclerosis
01/13
01/13
NCT01715207: Comparison of Aliskiren vs Negative Controls on Aortic Stiffness in Patients With MFS

Completed
3
30
RoW
Aliskiren, Rasilez, Atenolol, Tenormin
Samsung Medical Center
Marfan Syndrome
10/14
12/14
ATMOSPHERE, NCT00853658 / 2008-004104-31: Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbidity-mortality in Patients With Chronic Heart Failure

Completed
3
7064
Europe, Canada, Japan, US, RoW
Enalapril, Aliskiren, SPP100
Novartis Pharmaceuticals
Chronic Heart Failure
10/15
10/15

Download Options